<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808325</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-1409</org_study_id>
    <nct_id>NCT02808325</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy and Safety of Gelaspan</brief_title>
  <official_title>Prospective Controlled Randomized Double-blind Multicentre Study in Parallel Groups on the Efficacy and Safety of Gelaspan in Combination With Sterofundin ISO in Comparison With Gelofusine in Combination With Sodium Chloride Braun in Patients Scheduled for Abdominal or Pelvic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Medical LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the objective of the study to investigate the efficacy and safety of two different
      volume replacement regimens with gelatine solutions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Base Excess</measure>
    <time_frame>Change in base excess from baseline to end of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Base Excess</measure>
    <time_frame>Change in base excess from baseline to 12 hours after end of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>until 12 hours after end of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>until 12 hours after end of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>until 12 hours after end of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gas analysis</measure>
    <time_frame>until 12 hours after end of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation status</measure>
    <time_frame>until 12 hours after end of surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Hypovolemia</condition>
  <arm_group>
    <arm_group_label>balanced gelatine solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>isotonic colloidal volume substitute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-balanced gelatine solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>colloidal volume substitute</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelaspan 4%</intervention_name>
    <description>Gelaspan 4% combined with Sterofundin ISO</description>
    <arm_group_label>balanced gelatine solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelofusine 4%</intervention_name>
    <description>Gelofusine 4% combined with Sodium Chloride</description>
    <arm_group_label>non-balanced gelatine solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Male or female patients ≥ 18 years of age and ≤ 80 years of age.

          -  Patients scheduled to undergo open elective abdominal or pelvic surgery.

          -  Anticipated intraoperative volume requirement for gelatine solution is at least 15
             mL/kg body weight

          -  Negative pregnancy test (urine dipsticks) in women of child bearing potential.

          -  Provision of voluntary consent to participate in the study, following a full
             explanation of the nature and purpose of the study, by signing the informed consent
             form approved by the regulatory authorities of the Russian Federation and Local Ethics
             Committee (LEC) prior to all evaluations.

        Exclusion:

          -  Patients of ASA-class &gt; III.

          -  Known hypersensitivity to gelatine or to any of the constituents of the solution.

          -  Patients treated with other colloid solutions and / or blood products 24 hours prior
             to surgery.

          -  Patients on hemodialysis.

          -  Patients suffering from:

               -  Decompensated renal function (i.e. serum creatinine &gt; 3.0 mg/dL)

               -  Hypervolemia;

               -  Severe heart failure;

               -  Moderate lung edema;

               -  Hyperhydration;

               -  Severe blood coagulation disorders (aPTT &gt;2.5 x ULN or fibrinogen &lt; 0.5 x LLN or
                  INR &gt;2.5 x ULN);

               -  Hypernatremia (serum Na+ &gt; 150 mmol/L);

               -  Hyperchloremia (serum Cl- &gt; 110 mmol/L);

               -  Hypercalcemia (serum ionized Ca++ &gt; 1.5 mmol/L);

               -  Metabolic alkalosis;

               -  Severe generalized edema;

               -  Intracranial haemorrhage;

               -  Hyperkalemia (serum K+ &gt; 5.5 mmol/L).

          -  Pregnancy and/or nursing.

          -  Hypertension with the Systolic Blood Pressure &gt; 180 mm Hg and Diastolic Blood Pressure
             &gt; 110 mm Hg identified at screening.

          -  Patients who in the investigator's opinion couldn't take part in the study.

          -  Simultaneous participation in another clinical trial.

          -  Emergencies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Road Clinical Hospital of JSC &quot;Russian Railways</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western Federal Medical Research Center n.a. V.A. Almazov</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Dispensary</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polygeline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

